There is no single solution to the opioid crisis, but a combination of proven strategies has already shown measurable results in communities that commit to them. The crisis killed roughly 72,000 Americans in the 12 months ending September 2025, driven overwhelmingly by synthetic opioids like fentanyl. Solving it requires working multiple fronts simultaneously: keeping people alive in the short term, expanding access to effective treatment, reducing the oversupply of prescription opioids, and building the infrastructure to sustain all of it.
Medications That Cut Overdose Deaths in Half
The single most effective tool for keeping people with opioid use disorder alive is medication-based treatment. Methadone reduces opioid overdose deaths by 59% over 12 months compared to no medication. Buprenorphine reduces them by 38%. These aren’t medications that simply replace one drug with another. They stabilize brain chemistry, reduce cravings, and block the euphoric effects of other opioids, giving people the stability to rebuild their lives.
Despite this, most people who need these medications never receive them. Methadone can only be dispensed at federally licensed clinics, which are scarce in rural areas. Buprenorphine can be prescribed in a regular doctor’s office, but many physicians still don’t offer it. Expanding the number of providers who prescribe these medications, and removing bureaucratic barriers that delay treatment, is one of the highest-impact changes available. Every month a person waits for treatment is a month they remain at elevated risk of fatal overdose.
Adding behavioral incentives to medication makes treatment work even better. A large meta-analysis found that contingency management, where patients earn small rewards like gift cards for meeting treatment goals, resulted in 71.9% of participants doing better than the average person receiving standard care alone. It also improved medication adherence and therapy attendance. The approach is straightforward and inexpensive relative to the cost of untreated addiction.
Naloxone and Harm Reduction Save Lives Now
Not everyone with opioid use disorder is ready for treatment on any given day. Harm reduction strategies focus on keeping people alive until they are. Naloxone, the overdose-reversal medication, is the cornerstone. In Massachusetts, communities that trained more than 100 at-risk individuals in naloxone use saw a 46% reduction in opioid overdose deaths. Scotland achieved a 62% reduction when its national program distributed naloxone at scale.
Fentanyl test strips offer another layer of protection. Costing about a dollar each, they are 96 to 100% accurate at detecting fentanyl and can identify at least 10 fentanyl-related compounds. They aren’t perfect: carfentanyl, an extremely potent analog, is often missed because it appears in such tiny concentrations. False positives can also occur with methamphetamine or diphenhydramine if the sample isn’t properly diluted. Still, they give people critical information about what’s in their supply before they use it.
Syringe service programs, which provide clean needles and serve as a gateway to treatment, are associated with a 50% reduction in HIV and hepatitis C transmission. These programs do more than distribute supplies. They build trust with people who are often disconnected from healthcare, creating a bridge to medication, counseling, and social services when someone is ready.
Reducing the Prescription Pipeline
The crisis began with overprescribing, and while illicit fentanyl now drives most deaths, the flow of prescription opioids still matters. Prescription drug monitoring programs (PDMPs) are electronic databases that track controlled substance prescriptions, letting pharmacists and doctors see whether a patient is getting opioids from multiple sources. When states made PDMP checks mandatory before prescribing, the odds of “doctor shopping,” where a person visits multiple providers to stockpile pills, dropped by 80%. Fake prescriptions fell by 75%.
States that combined mandatory PDMP use with “pill mill” laws, which crack down on clinics that dispense opioids irresponsibly, saw prescribing rates decline by 10.6%, nearly double the 5.5% decline in states without those policies. These tools don’t prevent doctors from prescribing opioids when they’re genuinely needed. They target the patterns of excess that funnel pills into misuse.
Insurance Coverage Changes Who Gets Help
Treatment only works if people can access it, and for millions of low-income Americans, that access depends on insurance. In states that expanded Medicaid, the share of low-income adults receiving substance use treatment through Medicaid rose from 28.2% in 2012-2013 to 63.2% by 2016-2017. That’s a dramatic shift in who pays for care and, critically, who can afford it.
Expansion states also saw disproportionate increases in buprenorphine treatment among Medicaid beneficiaries. When the financial barrier drops, more people start the medications proven to keep them alive. The overall treatment rate in expansion states reached 13.5% of low-income adults with substance use disorders by 2016-2017, compared to 11.1% in non-expansion states. Those percentages are still far too low, but the gap illustrates how policy choices directly shape outcomes.
Protecting People Leaving Prison
The weeks after release from jail or prison are among the most dangerous periods for someone with opioid use disorder. Their tolerance has dropped during incarceration, but their access to drugs returns immediately. Before one major prison-based treatment program launched in Scotland, drug-related deaths occurred at a rate of 3.8 per 1,000 releases in the 12 weeks after leaving prison, with 57% of those deaths happening in the first two weeks.
After prisons began offering opioid treatment during incarceration, the death rate dropped to 2.2 per 1,000 releases. A separate naloxone training program for people leaving prison reduced opioid-related deaths in the four weeks after release by 20 to 36%. These are relatively simple interventions: start medication before release, and send people home with naloxone and the knowledge to use it. The challenge is scaling them across a fragmented corrections system where health services vary wildly from one facility to the next.
Where the Money Is Going
Funding is no longer the abstract problem it once was. Between 2022 and 2023, state and local governments received an estimated $6 billion in opioid settlement funds from lawsuits against pharmaceutical manufacturers and distributors. These funds are generally directed toward four categories: prevention, treatment, recovery, and harm reduction.
The settlement agreements lay out specific approved uses, including naloxone distribution, medication-based treatment, syringe service programs, support for pregnant and postpartum women, treatment for babies born with neonatal withdrawal, services for incarcerated populations, and data collection. The money exists. The question is whether it reaches the communities and programs where it will have the greatest impact, or gets absorbed into general budgets. Several states have established oversight boards to track spending, but accountability varies widely.
What Actually Moves the Needle
The opioid crisis persists not because solutions are unknown, but because proven approaches aren’t deployed at scale. Communities that have made real progress share common features: they treat addiction as a medical condition rather than a moral failing, they combine medication with practical supports like housing and employment, they fund harm reduction without ideological resistance, and they use data to target resources where overdose rates are highest.
No single policy eliminates the problem. Prescription monitoring means little if fentanyl flows freely through illicit markets. Naloxone saves a life in the moment but doesn’t treat the underlying disorder. Medication works, but only for people who can get to a provider and stay connected to care. The communities seeing declining overdose deaths are the ones layering these strategies on top of each other, closing the gaps between them, and sustaining the effort over years rather than election cycles.